Michael A Metzger, Chief Executive Officer at Syndax Pharmaceuticals, sold SNDX on Jul 8, 2026
Data as of Oct 27
▼ SELL$785K32,375 shares at $24.24Michael A Metzger Chief Executive OfficerSNDX Syndax Pharmaceuticals Inc
- Traded
- Jul 8, 2026
- Disclosed
- Jul 9, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
SNDX since disclosure
−44.9%
after the sale
Similar stocks (SPY) since disclosure
+2.4%
S&P 500 (SPY)
Change in closing price from Jul 9, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.